Jose Pablo Miramontes Gonzalez-rekin lankidetzan egindako argitalpenak (11)
2023
-
Biomarkers for immunotherapy in non-small cell lung cancer: a current and future reality
Precision Cancer Medicine
-
Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data
Cancers, Vol. 15, Núm. 17
-
Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis
Chinese Clinical Oncology, Vol. 12, Núm. 6
-
Reply to «Considerations to the manuscript cancer and elderly: Two incompatible concepts for intensive care?»
Revista Espanola de Geriatria y Gerontologia
2022
-
Cancer and elderly: Two incompatible concepts for intensive care?
Revista Espanola de Geriatria y Gerontologia
-
Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy
Frontiers in bioscience (Landmark edition), Vol. 27, Núm. 3, pp. 88
-
Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis
Biomedicines, Vol. 10, Núm. 2
2021
-
Dopamine receptors and the kidney: An overview of health-and pharmacological-targeted implications
Biomolecules, Vol. 11, Núm. 2, pp. 1-16
-
Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors
Life, Vol. 11, Núm. 12
-
Resistance to immune checkpoint inhibitors secondary to myeloid-derived suppressor cells: A new therapeutic targeting of haematological malignancies
Journal of Clinical Medicine, Vol. 10, Núm. 9
-
The influence of diet and probiotics on the response of solid tumours to immunotherapy: Present and future perspectives
Applied Sciences (Switzerland), Vol. 11, Núm. 18